Catalent licenses taste-masking technology for bitter drugs following R&D collaboration with NJIT

October 10th, 2012
Following a successful research collaboration with NJIT, Catalent Pharma Solutions of Somerset has announced that it has exclusively licensed innovative taste-making technology developed by NJIT Distinguished Professor Rajesh Davé, who was the principal investigator of a research project funded by Catalent. The technology will mask the most challenging, unpleasant and bitter tasting pharmaceutical active ingredients.

Under the terms of the license, Catalent will complete transfer of the technology into its world class, cGMP facilities to support manufacture of novel dosage forms such as its Zydis® fast dissolve platform. It is expected that the taste-masking technology will be effective for developing a wide variety of formulations including granules/sachets, sprinkles, chewables, effervescent and oral dispersible tablets.

"Taste-masking of fine drug particles has remained an un-met technical challenge for formulators," said Davé. "Through funding from Catalent we have been able to leverage our expertise to innovate technology and processes that allow for these materials to be cost effectively coated and taste-masked. This is a significant achievement for our team that included two highly-talented graduate students who delivered solutions to the Catalent challenge on time while developing strong fundamental science that would lead to journal articles."

Davé is a long-time faculty member of Newark College of Engineering's Department of Chemical, Biological and Pharmaceutical Engineering at NJIT.

Catalent Senior Vice President of Research and Development Kurt Nielsen commented, "Dr. Davé and his group at NJIT are leaders in particle science engineering, which has enabled a unique approach to API coating. It complements perfectly with Catalent's extensive dose form capabilities and will facilitate formulation of the most difficult-to-taste-mask actives. Catalent has already produced the first feasibility samples, which have exceeded our expectations. This technology will allow development of new dosage forms with the potential to deliver significant advantages to our customers and benefits to patients and consumers."

NJIT Associate Vice President of Technology Development Judith Sheft noted, "Collaboration with industry is an important element in the academic technology commercialization process. Industry can provide a focus, direction and input to an academic research agenda as well as the necessary resources to scale up early stage laboratory results. The project with Catalent is a wonderful example of a partnership between industry and academia that addresses both of these aspects."

Provided by New Jersey Institute of Technology

This Phys.org Science News Wire page contains a press release issued by an organization mentioned above and is provided to you “as is” with little or no review from Phys.Org staff.

More news stories

A new look at the sun's magnetic field

Sunspots, bursts of radiation and violent eruptions are signs that our sun is permanently active. Researchers have long known that this activity varies in a cycle of around eleven years' duration. Even if ...

Genetic test for inherited kidney diseases developed

Many kidney disorders are difficult to diagnose. To address this problem, scientists and clinicians have developed a diagnostic test that identifies genetic changes linked to inherited kidney disorders. This ...

Boys plagiarise more than girls at school

Research by the University of the Balearic Islands has analysed the phenomenon of academic plagiarism among secondary school students. The study, published in the journal Comunicar, confirms that this practi ...